Epidemiology : PTCLu represents the largest PTCL subtype in North Americaref. In the WHO classification PTCLu encompasses all of the PTCLs not classifiable as a specific disease entity in contrast to the rare, but "specified," subtypes. It is clear that this represents a heterogeneous group of diseases and although multiple morphologic subtypes have been recognized, evidence is lacking that these subtypes represent distinct clinicopathologic entities or have prognostic relevance
Symptoms & signs : most patients with PTCLu present with nodal involvement; however, a number of extranodal sites may also be involved (e.g., liver, bone marrow, gastrointestinal, skin)
Laboratory examinations :

Therapy : reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed PTCLref
Prognosis : the majority of series report a poor outcome with a 5-year overall survival of approximately 3035% using standard chemotherapyref1, ref2, ref3, ref4, ref5

Copyright © 2001-2014 Dr. Daniele Focosi. All rights reserved | About this site  | Terms of use | Legal notices
Make this website your default homepage | Add website to favourites  | Add this webpage to favourites  |    | Current link partners
Acknowledgements  |  Open forum  |  Abbreviations and acronyms  |  Medical terminology
Add a link  | Translate   | Softwares

This website subscribes to the HONcode principles of the HON Foundation. Click to verify.

 Search this site with : 
Rate this webpage :
Search Medical Dictionary